BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 31, 2015
View Archived Issues
Immune Pharmaceuticals enters exclusive license for novel bispecific antibody technology
Read More
University of Wisconsin generates vocal cord mucosae in vitro
Read More
HDAC inhibitor AR-42 prevents cancer cachexia in animal models
Read More
Initiation of phase III trial of CAM-2038 in opioid-dependent patients
Read More
Discovery Labs starts phase IIb trial of Aerosurf in premature infants with RDS
Read More
Minerva Neurosciences completes recruitment in phase IIb trial of MIN-101 in schizophrenia
Read More
FDA grants rare pediatric disease designation to RGX-111 for MPS I
Read More
TeaRx's oral anticoagulant Tearexaban completes phase II studies
Read More
Prexton Therapeutics plans first-in-human study of PXT-002331
Read More
Lixte licenses LB-100 rights in Asia to Taipei Medical University
Read More
Oryzon Genomics receives Spanish government funding for two projects
Read More
Six-panel biosignature shows promise as a point-of-care screening test for TB
Read More
Hutchison Medi Pharma plans phase I trial of HMPL-689
Read More
Epizyme starts trials of EZH2 inhibitor tazemetostat in INI1-negative tumors
Read More
CDK7 expression shows promise as a prognosis biomarker in TNBC
Read More
SNPs near CTNNA2 may be associated with impulsivity
Read More
NeuroDerm starts phase II trial comparing two dosing regimens of ND-0612H
Read More
Bristol-Myers Squibb patents MGAT2 inhibitors
Read More
GlaxoSmithKline describes STING modulators
Read More
Bristol-Myers Squibb reports development of NS5B inhibitors
Read More